Arla Foods Amba

Abbott Laboratories Corporation

Sarah S Comstock

Sharon Donovan

Peter Langborg Wejse

Anne Staudt Kvistgaard

Marcia H Monaco Siegel

Rachael Buck

Joseph P Schaller

Geralyn O Duska-McEwen

Geralyn Duska-Mcewen

Marcia H Siegel

The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof.

Mammalian milk osteopontin for enhancing immune responsiveness

Disclosed is a nutritional composition for use in modulating or reducing inflammation in an adult or elderly individual in need thereof. In some aspects, the nutritional composition comprises a neutral human milk oligosaccharide.

Nutritional formulations using human milk oligosaccharides for modulating inflammation

Growing community of inventors

East Lansing, MI, United States of America

Sarah S Comstock